The week's pattern is a three-front squeeze. Pharma is signing nine- and ten-figure enterprise AI deals as if the productivity case is settled. Hospitals are buying ambient scribes and clinical chatbots at the same pace, even as the first multi-site real-world data lands with a thud rather than a breakthrough. Regulators — FDA, CMS, state medical boards, the AMA — are spending the week reminding everyone that procurement is not policy. Capital is moving faster than the evidence, and faster still than the codes that would make the evidence matter.
The Big Story
Merck commits up to $1B to Google Cloud for an enterprise AI backbone · April 22, 2026 · [Fierce Pharma]
→ Merck's deal — covering R&D, manufacturing, commercial and corporate functions — lands eight days after Novo Nordisk's enterprise pact with OpenAI, and the same day OpenAI rolled out a free clinician tier of ChatGPT. The signal to pharma operators: the unit of AI procurement is no longer a discovery-platform license but a multi-year, all-of-enterprise compute and agent commitment priced like an ERP migration. Expect IT and procurement, not chief scientific officers, to own the next round of negotiations.
Also This Week
OpenAI launches free ChatGPT for Clinicians with HealthBench Professional · April 22, 2026 · [OpenAI]
→ Free tier for verified US physicians, NPs, PAs and pharmacists with clinical search, documentation and deep-research workflows; AMA data cited at launch puts physician AI use at 72% — which is exactly why the AMA spent the same week demanding a regulatory crackdown on consumer wellness chatbots.
UnitedHealth confirms a $3B AI build-out, with $1.6B to be spent in 2026 · April 6, 2026 · [STAT]
→ 22,000 engineers, an Avery chatbot scaling from 6.5M to 20.5M members by year-end, and AI agents writing claims, codes and prior-auth decisions — the largest corporate AI commitment in healthcare history, and the one most likely to define what "AI in care" actually means at the bedside.
Utah Medical Licensing Board demands suspension of Doctronic AI prescribing pilot · April 24, 2026 · [STAT]
→ The board says it learned of the $4-per-renewal program after launch and calls it a patient-safety risk; Utah's Department of Commerce insists a licensed physician reviews every script. The first state-level confrontation between an AI-policy office and a medical board — and a template for the next dozen.
Aidoc's multi-condition abdominal CT triage tool clears FDA · January / re-listed April 2026 · [STAT]
→ Single algorithm flagging liver injury, spleen injury and appendicitis from one abdominal CT — part of a broader FDA list update putting radiology AI authorizations past 1,100 devices, 76% of all AI-enabled clearances. The bottleneck has fully shifted from clearance to deployment.
Q1 digital health funding hits $4B across 110 deals; AI is no longer a category · April 2026 · [Fierce Healthcare]
→ Twelve megadeals drove the quarter — WHOOP $575M, Verily $300M, OpenEvidence $250M, Talkiatry $210M — and Rock Health stopped breaking out "AI" as a separate slice because every digital health company now claims it. Concentration, not breadth, is the story.
From the Lab
Changes in Clinician Time Expenditure and Visit Quantity With AI-Powered Scribes: A Multisite Study · April 2026 · [JAMA]
→ The largest real-world ambient-scribe evaluation to date — 8,581 ambulatory clinicians across Mass General Brigham, Emory, UCSF, Yale New Haven and UC Davis, with 1,809 adopters tracked over two years — found 13 minutes/day less in the EHR, 16 minutes less documenting, and roughly half an extra visit per week. Real, but modest: nowhere near the 60-90 minute claims in vendor decks, and the senior author cautions the time saved is too small to explain reported burnout reductions. Operators rebuilding ROI models should expect payback periods to lengthen 30-50%.
Is AI actually improving healthcare? · April 21, 2026 · [Nature Medicine]
→ Goldenberg and Wiens argue the field has confused model performance with clinical impact and that the next generation of evaluations needs prospective, comparative-to-standard-of-care designs that isolate AI attribution. Paired with a companion piece in the same issue demanding stronger evidence before clinical-impact claims, this is the journal clinicians and payers will both cite when pushing back on procurement timelines.
Worth Reading
- [AI could check millions of lung-cancer scans for heart risk. Who will pay for it?] — The clearest illustration this week of the reimbursement-code problem: opportunistic AI-CAC scoring on the ~19M non-gated chest CTs done annually is nearly free clinical value the payment system has no way to recognize.
- [Insilico Medicine's CEO on how to be productive in AI drug development] — Zhavoronkov on Phase 2a rentosertib data and the operating discipline behind the only AI-discovered drug to clear a meaningful efficacy bar this cycle. Useful counter-narrative to "AI biotech winter" framing.
- [Policy brief: ambient AI scribes and the coding arms race] — The under-discussed second-order effect of scribes: more granular notes drive higher E/M and risk-adjustment coding, which is already triggering payer downcoding and HCC recalibration. Hospital CFOs should read this before the next contract cycle.
Contracts get signed in dollars; clinical impact gets settled in minutes per visit and CPT codes. We're early on both.
— Alexis